MallyaD injection pen adapter (MallyaD)

K250555 · Biocorp Production · QOG · Mar 27, 2025 · General Hospital

Device Facts

• Record ID: K250555
• Device Name: MallyaD injection pen adapter (MallyaD)
• Applicant: Biocorp Production
• Product Code: QOG · General Hospital
• Decision Date: Mar 27, 2025
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 880.5860
• Device Class: Class 2

Indications for Use

The MallyaD Injection Pen Adapter is indicated for the capture and wireless transmission of compatible reusable and disposable pen injectors. The Novo Nordisk PDS290 Injection pens compatible for diabetes treatment are: - insulin degludec molecule (Tresiba U-100 FlexTouch and Tresiba U-200 FlexTouch) - insulin aspart molecule (Fiasp FlexTouch) - insulin degludec and liraglutide molecules (Xultophy)

Device Story

MallyaD is a smart sensor adapter that attaches to the button of compatible Novo Nordisk PDS290 injection pens. It captures dosing information by sensing the rotation of the pen's dosing mechanism during dose setting. The device transmits the dialed dose increment, date, and time of injection via Bluetooth Low Energy (BLE) to a mobile application. It is intended for use by patients or caregivers in home or clinical environments. The device provides visual feedback via an LED. It does not control or impact drug delivery. By automating the logging of injection data, it assists patients in tracking their diabetes treatment adherence. The device is rechargeable via USB and has a 3-year lifetime.

Clinical Evidence

Bench testing only. Performance verified per ISO 11608-1 guidelines. Testing confirmed 99% dose recording accuracy (within +/- 1 increment). Additional testing included biocompatibility (ISO 10993-1), electrical safety/EMC (IEC 60601-1/2/11), and cybersecurity/software validation. Human factors validation confirmed usability of the device form factor.

Technological Characteristics

Smart sensor adapter; 25.8mm diameter, 40.1mm height. Sensing via mechanical rotation of pen dosing button. Connectivity: Bluetooth Low Energy (BLE). Power: Non-replaceable rechargeable battery. Biocompatibility: ISO 10993-1 (permanent contact with intact skin). Standards: ISO 11608-1 (dose accuracy), IEC 60601-1/2/11 (electrical/EMC).

Indications for Use

Indicated for capture and wireless transmission of dosing information from compatible reusable and disposable pen injectors for patients with diabetes using Novo Nordisk PDS290 platform pens (Tresiba U-100/U-200 FlexTouch, Fiasp FlexTouch, Xultophy).

Regulatory Classification

Identification

A piston syringe is a device intended for medical purposes that consists of a calibrated hollow barrel and a movable plunger. At one end of the barrel there is a male connector (nozzle) for fitting the female connector (hub) of a hypodermic single lumen needle. The device is used to inject fluids into, or withdraw fluids from, the body.

Predicate Devices

• SoloSmart Injection Pen Adapter (K231820)

Submission Summary (Full Text)

{0}------------------------------------------------

March 27, 2025

Image /page/0/Picture/1 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

BioCorp Production Alexia Garin QARA Director ZI de Lavaur La Bechade Issoire, 63500 France

Re: K250555

Trade/Device Name: MallyaD injection pen adapter (MallyaD) Regulation Number: 21 CFR 880.5860 Regulation Name: Piston Syringe Regulatory Class: Class II Product Code: QOG Dated: February 18, 2025 Received: February 25, 2025

Dear Alexia Garin:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

{1}------------------------------------------------

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rue"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

{2}------------------------------------------------

Sincerely,

# Shruti N. Mistry -S

Shruti Mistry Assistant Director DHT3C: Division of Drug Delivery and General Hospital Devices, and Human Factors OHT3: Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

# Indications for Use

510(k) Number (if known) K250555

Device Name MallyaD injection pen adapter (MallyaD)

Indications for Use (Describe)

The MallyaD Injection Pen Adapter is indicated for the capture and wireless transmission of compatible reusable and disposable pen injectors.

The Novo Nordisk PDS290 Injection pens compatible for diabetes treatment are:

- insulin degludec molecule (Tresiba U-100 FlexTouch and Tresiba U-200 FlexTouch)

- insulin aspart molecule (Fiasp FlexTouch)
- insulin degludec and liraglutide molecules (Xultophy)

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

X Over-The-Counter Use (21 CFR 801 Subpart C)

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the logo for Biocorp, a Novo Nordisk company. The logo is in a dark gray color and features the word "BIOCORP" in a bold, sans-serif font. The two O's in the word are interlocked, creating a visual link. Below the word "BIOCORP" is the text "a novo nordisk company" in a smaller font size.

MALLYAP

## 510(k) Summary - K250555

| 1 SUBMITTER | |
|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| Applicant: | Biocorp Production<br>ZI Lavaur La Béchade<br>63500 Issoire - France |
| Prepared By:<br>Date Prepared: | Alexia Garin<br>March 26, 2025 |
| 2 DEVICE | |
| Trade/Proprietary Name:<br>Common/Usual Name:<br>Classification Name:<br>Product Code:<br>Class: | MallyaD Injection Pen Adapter (MallyaD)<br>Injection Data Capture Device<br>21 CFR §880.5860 Piston Syringe<br>QOG<br>II |

### 3 PREDICATE DEVICE

K231820, Biocorp Production, SoloSmart Injection Pen Adapter (SoloSmart®).

### 4 SUBSTANTIAL EQUIVALENCE

The Mallyaº Injection Pen Adapter device is substantially equivalent to the SoloSmart® (K231820). The device has the same indication for use, intended use and same fundamental scientific technology.

## 4.1 DEVICE DESCRIPTION

The concerned Mallya Injection Pen Adapter, also called Mallyaº, is a smart sensor composed of a button to be assembled onto a pen injector by covering the injection pen button. It is designed to be mounted on specific Novo Nordisk® PDS290 platform injection pens. A USB cable, necessary to charge the Mallya® device is also provided in the package.

## 4.2 TECHNOLOGICAL CHARACTERISTICS

The Mallya® has the same technological characteristics as the predicate device to capture and transmit dosing information. The information is captured through the rotation of the dosing button of the pen into a value indicating the dose increment injected. Both the Mallyaº and the predicate device use same Low Energy Bluetooth (BLE) communication technology and same protocol to pair and transmit the information to a mobile device with a compatible app.

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image shows the logo for BICORP, a Novo Nordisk company. The logo is in a dark gray color and features the word "BICORP" in a bold, sans-serif font. The two O's in the word are interlocked. Below the word "BICORP" is the text "a novo nordisk company" in a smaller, lighter font.

## 4.3 INDICATIONS FOR USE

The Mallyaº is indicated for the capture and wireless transmission of dosing information of compatible reusable and disposable pen injectors.

The Novo Nordisk PDS290 Injection pens compatible for diabetes treatment are:

- insulin degludec molecule (Tresiba U-100 FlexTouch and Tresiba U-200 FlexTouch)
- insulin aspart molecule (Fiasp FlexTouch)
- insulin degludec and liraglutide molecules (Xultophy)

## 4.4 DEVICE PHYSICAL DESCRIPTION

The device is made of a cap to be assembled onto a pen injector by covering the injection pen button. The overall device size is 25.8 mm diameter and 40.1 mm height. A USB cable, necessary to charge the Mallya® device is also provided in the package.

| Attribute | Subject Device | Predicate device | | | | | | | | | |
|---------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|--|--|--|--|--|--|--|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Device Name/<br>Brandname | MallyaD Injection Pen Adapter<br>MallyaD | SoloSmart Injection Pen Adapter<br>SoloSmart | | | | | | | | | |
| | | Data Capture and Transmission Technology | | | | | | | | | |
| 510(k) Number | K250555 | K231820 | | | | | | | | | |
| Attribute | Subject Device | Predicate device | Discussion/<br>Comments | | | | | | | | |
| Classification-<br>Product Code | Class 2 - QOG | Class 2 - QOG | Same | | | | | | | | |
| Indication for<br>Use | The MallyaD Injection Pen Adapter is<br>indicated for the capture and wireless<br>transmission of dosing information of<br>compatible reusable and disposable<br>pen injectors.<br><br>The Novo Nordisk PDS290 Injection<br>pens compatible for diabetes<br>treatment are:<br>- insulin degludec molecule (Tresiba<br>U-100 FlexTouch and Tresiba U-200<br>FlexTouch)<br>- insulin aspart molecule (Fiasp<br>FlexTouch)<br>- insulin degludec and liraglutide<br>molecules (Xultophy) | The SoloSmart Injection Pen Adapter is<br>indicated for the capture and wireless<br>transmission of dosing information<br>from compatible reusable and<br>disposable pen injectors.<br><br>The following Injection pens are<br>compatible:<br>DEVICE MODEL<br>NAME INSULIN<br>BRAND NAME MOLECULE NAME MOLECULE<br>CONCENTRATION SoloSmart®<br>designed for<br>SoloStar®<br>SANOFI injection<br>pen Lantus<br>Toujeo<br>Admelog<br>Apidra<br>Soliqua 100/33 GLARGINE<br>GLARGINE<br>LISPRO<br>GLULISINE<br>GLARGINE AND<br>LIXISENATIDE 100 IU/mL<br>300 IU/mL<br>100 IU/mL<br>100 IU/mL<br>100 IU/mL<br>+33 mcg/mL | | | | | | | | | Similar indication<br>for use,<br>compatibility with<br>different<br>manufacturer<br>injection pen for<br>same therapeutic<br>area. Verification<br>tests conducted<br>with compatible<br>pen. |
| Type of pens | The following Novo Nordisk PDS290<br>pen platform are compatible:<br>Tresiba® U-100 FlexTouch® and<br>Tresiba® U-200 FlexTouch®, Fiasp®<br>FlexTouch®,Xultophy® | The following Sanofi SoloStar® Injection<br>pens are compatible: Lantus<br>Toujeo Toujeo Max Aprida<br>Soliqua 100/33 | Compatible with a<br>different pen<br>platform: Novo<br>Nordisk PDS290.<br>Verification tests<br>conducted with the<br>compatible pen. | | | | | | | | |

## 4.5 SUBSTANTIAL EQUIVALENCE DISCUSSION

{6}------------------------------------------------

Image /page/6/Picture/0 description: The image shows the logo for Biocorp, a Novo Nordisk company. The logo is in a dark gray color and features the word "BIOCORP" in a bold, sans-serif font. The two O's in the word are linked together, creating a visual element that resembles a chain or connection. Below the word "BIOCORP" is the text "a novo nordisk company" in a smaller font.

MALLYAº

| Attribute | Subject Device | Predicate device | |
|-------------------------------------------|---------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Single patient<br>Use | Yes | Yes | Same |
| Reusable<br>Device | Yes | Yes | Same |
| Intended Use | Intended to be used by patients in the<br>same use environment as their<br>compatible injection pen. | Intended to be used by patients in the<br>same use environment as their<br>compatible injection pen. | Same |
| Prescription<br>use | No | No | Same |
| User Group | User of Compatible Injection Pens;<br>includes patients or patient<br>relatives/caregiver | User of Compatible Injection Pens;<br>includes patients or patient<br>relatives/caregiver | |
| User Feedback | Electronic - LED (light) | Electronic - LED (light) | Same type of<br>coloured light<br>indication adapted<br>to pen mechanical<br>behaviour.<br>Software<br>verification tests<br>conducted with the<br>compatible pen. |
| Wireless<br>Connectivity | Bluetooth Low Energy (BLE) | Bluetooth Low Energy (BLE) | Same connectivity<br>BLE protocol |
| Control or<br>impact Drug<br>delivery | No | No | Same |
| Fluid Pathway<br>Contact | None | None | Same |
| Software<br>controlled | Yes | Yes | Same |
| Dose Recorded | Calculated based on dose increment<br>set | Calculated based on dose delivered | Change from<br>predicate adapted<br>to pen mechanical<br>behaviour. |
| Information<br>Transmitted | Dialed dose increment, and time and<br>date of injection | Delivered dose, and time and date of<br>injection | Dose recording<br>accuracy<br>verification tests<br>conducted with the<br>compatible pen. |
| Mechanism for<br>Recording dose<br>dialed | Sense dose increment dialed through<br>movement and rotation of dosing<br>mechanism during dose setting | Sense dose increment delivered<br>through rotation of dosing mechanism<br>during dose administration | |
| Differentiates<br>Prime vs. Dose | Yes | Yes | Same |
| Battery | Non-Replaceable; Rechargeable | Non-Replaceable; Rechargeable | Same |
| Lifetime | Up to 3 years of use from<br>manufacturing date | Up to 3 years of use from<br>manufacturing date | Same |

{7}------------------------------------------------

Image /page/7/Picture/0 description: The image shows the logo for BICORP, a Novo Nordisk company. The logo is in a dark gray color and features the word "BICORP" in a bold, sans-serif font. The two O's in the word are designed to look like interlocking links of a chain. Below the word "BICORP" is the text "a novo nordisk company" in a smaller, sans-serif font.

.

MALLYAP

## 5 SIGNIFICANT PERFORMANCE CHARACTERISTICS

### 5.1 PERFORMANCE CLAIMS

Mallyaº claims are based on the reported dose accuracy:

- Device accuracy: 99% of the recorded doses match the dialed doses with a margin of error of +/- 1 increment.
### 5.2 SUPPORTING PERFORMANCE DATA

Data on the following testing were generated verifying the design of the device:

- Bench testing on performance, using ISO 11608-1 as a guide.
- Dose accuracy of pen is not affected by Mallya® ●
- . Recording and transmission Accuracy
- . Dose Prime Differentiation
- . Complete Dose Notification
- Incomplete Injection Identification
- Physical Interaction with pen, including force to mount, maintain and remove Mallya®
- Biocompatibility –FDA guidance; permanent contact with intact skin based on ● ISO10993-1.
- Lifetime The product met test criteria to verify it will operate/function before the ● expiration date of 3 years including storage and Use Lifetime.
- Electrical safety, EMC and Radiocommunication per FDA Guidelines based on ● IEC 60601-1 and appropriate collateral requirements from IEC 60601-2 and IEC 60601-1-11
- Cybersecurity Testing and Software Verification and Validation per FDA ● Guidelines

### 5.3 HUMAN FACTOR VALIDATION

Biocorp performed a HF impact assessment for performance and safety validation to confirm the usability of the device form factor and associated instructions for use per FDA guidance.

#### 6 CONCLUSION

Biocorp as concluded that the evidence documented during design control activities supports that the Mallya® Injection Pen Adapter (Mallyaº), is substantially equivalent to the predicate for specific indications and technological characteristics of the predicate device with regards to the data recording and transmission.

#### 7 CONTACT PERSON

Alexia Garin, [e-mail] [phone]